Irritable bowel syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 84: Line 84:
* IBS patients have higher [[Mucous membrane|mucosal]] counts of ''[[Lymphocyte|lymphocytes]]'' (T cells, B cells), ''[[Mast cell|mast]] cells'' and immune ''mediators'' such as prostanoids, [[Protease|proteases]], [[Cytokine|cytokines]] and [[Histamine|histamines]].<ref name="pmid17383420" /><ref name="pmid20427395">{{cite journal |vauthors=Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM |title=Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery |journal=Gut |volume=59 |issue=5 |pages=605–11 |year=2010 |pmid=20427395 |doi=10.1136/gut.2009.202234 |url=}}</ref><ref name="pmid21911849">{{cite journal |vauthors=Wensaas KA, Langeland N, Hanevik K, Mørch K, Eide GE, Rortveit G |title=Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study |journal=Gut |volume=61 |issue=2 |pages=214–9 |year=2012 |pmid=21911849 |doi=10.1136/gutjnl-2011-300220 |url=}}</ref><ref name="pmid19711225">{{cite journal |vauthors=Mearin F, Perelló A, Balboa A, Perona M, Sans M, Salas A, Angulo S, Lloreta J, Benasayag R, García-Gonzalez MA, Pérez-Oliveras M, Coderch J |title=Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis |journal=Scand. J. Gastroenterol. |volume=44 |issue=10 |pages=1173–85 |year=2009 |pmid=19711225 |doi=10.1080/00365520903171276 |url=}}</ref><ref name="pmid12631663">{{cite journal |vauthors=Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM |title=Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome |journal=Gut |volume=52 |issue=4 |pages=523–6 |year=2003 |pmid=12631663 |pmc=1773606 |doi= |url=}}</ref>
* IBS patients have higher [[Mucous membrane|mucosal]] counts of ''[[Lymphocyte|lymphocytes]]'' (T cells, B cells), ''[[Mast cell|mast]] cells'' and immune ''mediators'' such as prostanoids, [[Protease|proteases]], [[Cytokine|cytokines]] and [[Histamine|histamines]].<ref name="pmid17383420" /><ref name="pmid20427395">{{cite journal |vauthors=Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM |title=Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery |journal=Gut |volume=59 |issue=5 |pages=605–11 |year=2010 |pmid=20427395 |doi=10.1136/gut.2009.202234 |url=}}</ref><ref name="pmid21911849">{{cite journal |vauthors=Wensaas KA, Langeland N, Hanevik K, Mørch K, Eide GE, Rortveit G |title=Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study |journal=Gut |volume=61 |issue=2 |pages=214–9 |year=2012 |pmid=21911849 |doi=10.1136/gutjnl-2011-300220 |url=}}</ref><ref name="pmid19711225">{{cite journal |vauthors=Mearin F, Perelló A, Balboa A, Perona M, Sans M, Salas A, Angulo S, Lloreta J, Benasayag R, García-Gonzalez MA, Pérez-Oliveras M, Coderch J |title=Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis |journal=Scand. J. Gastroenterol. |volume=44 |issue=10 |pages=1173–85 |year=2009 |pmid=19711225 |doi=10.1080/00365520903171276 |url=}}</ref><ref name="pmid12631663">{{cite journal |vauthors=Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM |title=Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome |journal=Gut |volume=52 |issue=4 |pages=523–6 |year=2003 |pmid=12631663 |pmc=1773606 |doi= |url=}}</ref>
** '''Lymphocytes:'''
** '''Lymphocytes:'''
**Activation of [[humoral immunity]] in [[Irritable bowel syndrome|IBS]] is specific for the [[gastrointestinal tract]]. Increased number of [[Lymphocyte|lymphocytes]] have been found in the [[small intestine]] and [[Colon (anatomy)|colon]] of [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid12055584" /><ref name="pmid12454854" /><ref name="pmid19222763">{{cite journal |vauthors=Ohman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M |title=B-cell activation in patients with irritable bowel syndrome (IBS) |journal=Neurogastroenterol. Motil. |volume=21 |issue=6 |pages=644–50, e27 |year=2009 |pmid=19222763 |doi=10.1111/j.1365-2982.2009.01272.x |url=}}</ref><ref name="pmid25209656">{{cite journal |vauthors=Vicario M, González-Castro AM, Martínez C, Lobo B, Pigrau M, Guilarte M, de Torres I, Mosquera JL, Fortea M, Sevillano-Aguilera C, Salvo-Romero E, Alonso C, Rodiño-Janeiro BK, Söderholm JD, Azpiroz F, Santos J |title=Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations |journal=Gut |volume=64 |issue=9 |pages=1379–88 |year=2015 |pmid=25209656 |doi=10.1136/gutjnl-2013-306236 |url=}}</ref>
***Activation of [[humoral immunity]] in [[Irritable bowel syndrome|IBS]] is specific for the [[gastrointestinal tract]]. Increased number of [[Lymphocyte|lymphocytes]] have been found in the [[small intestine]] and [[Colon (anatomy)|colon]] of [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid12055584" /><ref name="pmid12454854" /><ref name="pmid19222763">{{cite journal |vauthors=Ohman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M |title=B-cell activation in patients with irritable bowel syndrome (IBS) |journal=Neurogastroenterol. Motil. |volume=21 |issue=6 |pages=644–50, e27 |year=2009 |pmid=19222763 |doi=10.1111/j.1365-2982.2009.01272.x |url=}}</ref><ref name="pmid25209656">{{cite journal |vauthors=Vicario M, González-Castro AM, Martínez C, Lobo B, Pigrau M, Guilarte M, de Torres I, Mosquera JL, Fortea M, Sevillano-Aguilera C, Salvo-Romero E, Alonso C, Rodiño-Janeiro BK, Söderholm JD, Azpiroz F, Santos J |title=Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations |journal=Gut |volume=64 |issue=9 |pages=1379–88 |year=2015 |pmid=25209656 |doi=10.1136/gutjnl-2013-306236 |url=}}</ref>  
**[[Irritable bowel syndrome|IBS]] patients with [[diarrhea]] have enhanced [[Mucous membrane|mucosal]] [[Humoral immunity|humoral]] activity, associated with activation and [[Cell growth|proliferation]] of [[B cell|B cells]] and [[Antibody|immunoglobulin]] production, identified by microarray profiling.<ref name="pmid25209656" />
***[[Irritable bowel syndrome|IBS]] patients with [[diarrhea]] have enhanced [[Mucous membrane|mucosal]] [[Humoral immunity|humoral]] activity, associated with activation and [[Cell growth|proliferation]] of [[B cell|B cells]] and [[Antibody|immunoglobulin]] production, identified by microarray profiling.<ref name="pmid25209656" />  
**[[Irritable bowel syndrome|IBS]] patients with severe disease have an increase in [[lymphocyte]] [[Infiltration (medical)|infiltration]] in the myentric plexus.<ref name="pmid12454854" />
***[[Irritable bowel syndrome|IBS]] patients with severe disease have an increase in [[lymphocyte]] [[Infiltration (medical)|infiltration]] in the myentric plexus.<ref name="pmid12454854" />  
**Mediators released by [[Lymphocyte|lymphocytes]] include [[histamine]], [[Protease|proteases]] and [[nitric oxide]]. The stimulation of the [[enteric nervous system]] by these mediators leads to abnormal [[Viscus|visceral]] and [[Muscle|motor]] responses within the [[gastrointestinal tract]].<ref name="pmid12055584" />
***Mediators released by [[Lymphocyte|lymphocytes]] include [[histamine]], [[Protease|proteases]] and [[nitric oxide]]. The stimulation of the [[enteric nervous system]] by these mediators leads to abnormal [[Viscus|visceral]] and [[Muscle|motor]] responses within the [[gastrointestinal tract]].<ref name="pmid12055584" />  
**Stool in patients with [[diarrhea]] prominent [[Irritable bowel syndrome|IBS]] demonstrates high levels of [[serine]] [[protease]] activity, which is produced by [[Lymphocyte|lymphocytes]].<ref name="pmid18924448">{{cite journal |vauthors=Bueno L |title=Protease activated receptor 2: a new target for IBS treatment |journal=Eur Rev Med Pharmacol Sci |volume=12 Suppl 1 |issue= |pages=95–102 |year=2008 |pmid=18924448 |doi= |url=}}</ref><ref name="pmid18194983">{{cite journal |vauthors=Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L |title=Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity |journal=Gut |volume=57 |issue=5 |pages=591–9 |year=2008 |pmid=18194983 |doi=10.1136/gut.2007.140210 |url=}}</ref>
***Stool in patients with [[diarrhea]] prominent [[Irritable bowel syndrome|IBS]] demonstrates high levels of [[serine]] [[protease]] activity, which is produced by [[Lymphocyte|lymphocytes]].<ref name="pmid18924448">{{cite journal |vauthors=Bueno L |title=Protease activated receptor 2: a new target for IBS treatment |journal=Eur Rev Med Pharmacol Sci |volume=12 Suppl 1 |issue= |pages=95–102 |year=2008 |pmid=18924448 |doi= |url=}}</ref><ref name="pmid18194983">{{cite journal |vauthors=Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L |title=Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity |journal=Gut |volume=57 |issue=5 |pages=591–9 |year=2008 |pmid=18194983 |doi=10.1136/gut.2007.140210 |url=}}</ref>  
**In response to high levels of [[serine protease]], there is increased [[Viscus|visceral]] pain and [[Colon (anatomy)|colonic]] cellular permeability. <ref name="pmid18924448" />
***In response to high levels of [[serine protease]], there is increased [[Viscus|visceral]] pain and [[Colon (anatomy)|colonic]] cellular permeability. <ref name="pmid18924448" />  
**[[Serine protease]] inhibitors prevent effects mediated by high levels of [[serine protease]] in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid18194983" /><ref name="pmid18924448" />
***[[Serine protease]] inhibitors prevent effects mediated by high levels of [[serine protease]] in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid18194983" /><ref name="pmid18924448" />
**'''Mast cells:'''
**'''Mast cells:'''
**  [[Irritable bowel syndrome|IBS]] leads to an increased number of [[Mast cell|mast cells]] in [[Irritable bowel syndrome|IBS]] patients in the [[jejunum]], [[terminal ileum]] and [[Colon (anatomy)|colon]].<ref name="pmid14988823" />
***  [[Irritable bowel syndrome|IBS]] leads to an increased number of [[Mast cell|mast cells]] in [[Irritable bowel syndrome|IBS]] patients in the [[jejunum]], [[terminal ileum]] and [[Colon (anatomy)|colon]].<ref name="pmid14988823" />  
** Higher numbers of activated [[Mast cell|mast cells]] are found in proximity to [[Colon (anatomy)|colonic]] nerve fibres in the mucosa of the [[Gastrointestinal tract|gastrointestinal]] [[tract]] of [[Irritable bowel syndrome|IBS]] patients. <ref name="pmid14988823" /><ref name="pmid17005763" />
*** Higher numbers of activated [[Mast cell|mast cells]] are found in proximity to [[Colon (anatomy)|colonic]] nerve fibres in the mucosa of the [[Gastrointestinal tract|gastrointestinal]] [[tract]] of [[Irritable bowel syndrome|IBS]] patients. <ref name="pmid14988823" /><ref name="pmid17005763" />
** '''Proinflammatory cytokines:'''
** '''Proinflammatory cytokines:'''
** [[Cytokine|Cytokines]] are protein mediators of the [[Immunity (medical)|immune]] response.  Increased levels of [[Cytokine|cytokines]] have been found in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid12631663" /><ref name="pmid19711225" />
*** [[Cytokine|Cytokines]] are protein mediators of the [[Immunity (medical)|immune]] response. Increased levels of [[Cytokine|cytokines]] have been found in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid19711225" /><ref name="pmid12631663" />  
** Higher amounts of [[Tumour necrosis factor|tumor necrosis factor]] are produced by the peripheral blood [[Monocyte|mononuclear]] cells of [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid16472586">{{cite journal |vauthors=Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW |title=Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? |journal=Gastroenterology |volume=130 |issue=2 |pages=304–11 |year=2006 |pmid=16472586 |doi=10.1053/j.gastro.2005.11.033 |url=}}</ref><ref name="pmid17383420" />
*** Higher amounts of [[Tumour necrosis factor|tumor necrosis factor]] are produced by the peripheral blood [[Monocyte|mononuclear]] cells of [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid17383420" /><ref name="pmid16472586">{{cite journal |vauthors=Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW |title=Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? |journal=Gastroenterology |volume=130 |issue=2 |pages=304–11 |year=2006 |pmid=16472586 |doi=10.1053/j.gastro.2005.11.033 |url=}}</ref>
** Other [[Cytokine|cytokines]] such as [[Interleukin|interleukin 1β]], [[interleukin]] 6,  [[Interleukin 10|interleukin10]], and [[Tumor necrosis factor-alpha|TNFα]] are raised in [[Irritable bowel syndrome|IBS]] patients.
*** Other [[Cytokine|cytokines]] such as [[Interleukin|interleukin 1β]], [[interleukin]] 6,  [[Interleukin 10|interleukin10]], and [[Tumor necrosis factor-alpha|TNFα]] are raised in [[Irritable bowel syndrome|IBS]] patients.
** Increased concentration of [[Cytokine|cytokines]] is directly proportional to the severity and frequency of pain.<ref name="pmid17383420" /><ref name="pmid25063707" /><ref name="pmid16472586" />
*** Increased concentration of [[Cytokine|cytokines]] is directly proportional to the severity and frequency of pain.<ref name="pmid17383420" /><ref name="pmid16472586" /><ref name="pmid25063707" />  
** The [[Tumor necrosis factors|TNF]] [[antagonist]] [[infliximab]] counteracts pain in [[Irritable bowel syndrome|IBS]] patients, proving [[Tumor necrosis factors|TNF]] involvement in mechanical [[hypersensitivity]] of the [[Colon (anatomy)|colonic]] [[afferent nerve]] endings . <ref name="pmid25063707">{{cite journal |vauthors=Hughes PA, Moretta M, Lim A, Grasby DJ, Bird D, Brierley SM, Liebregts T, Adam B, Blackshaw LA, Holtmann G, Bampton P, Hoffmann P, Andrews JM, Zola H, Krumbiegel D |title=Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients |journal=Brain Behav. Immun. |volume=42 |issue= |pages=191–203 |year=2014 |pmid=25063707 |doi=10.1016/j.bbi.2014.07.001 |url=}}</ref>
*** The [[Tumor necrosis factors|TNF]] [[antagonist]] [[infliximab]] counteracts pain in [[Irritable bowel syndrome|IBS]] patients, proving [[Tumor necrosis factors|TNF]] involvement in mechanical [[hypersensitivity]] of the [[Colon (anatomy)|colonic]] [[afferent nerve]] endings.<ref name="pmid25063707">{{cite journal |vauthors=Hughes PA, Moretta M, Lim A, Grasby DJ, Bird D, Brierley SM, Liebregts T, Adam B, Blackshaw LA, Holtmann G, Bampton P, Hoffmann P, Andrews JM, Zola H, Krumbiegel D |title=Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients |journal=Brain Behav. Immun. |volume=42 |issue= |pages=191–203 |year=2014 |pmid=25063707 |doi=10.1016/j.bbi.2014.07.001 |url=}}</ref>
* '''Altered gut microbiota'''
* '''Altered gut microbiota'''
** [[Gut flora|Fecal microflora]] in [[Irritable bowel syndrome|IBS]] patients differ from healthy individuals. Some IBS patients have [[Colon (anatomy)|colonic]] [[Spirochaete|spirochaetosis]], with a unique pathology of increased [[Lymphatic system|lymphoid]] follicles and [[Eosinophil granulocyte|eosinophils]] on [[histology]].<ref name="pmid20427395" /><ref name="pmid25540866">{{cite journal |vauthors=Walker MM, Talley NJ, Inganäs L, Engstrand L, Jones MP, Nyhlin H, Agréus L, Kjellstrom L, Öst Å, Andreasson A |title=Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden |journal=Hum. Pathol. |volume=46 |issue=2 |pages=277–83 |year=2015 |pmid=25540866 |doi=10.1016/j.humpath.2014.10.026 |url=}}</ref><ref name="pmid17631127">{{cite journal |vauthors=Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A |title=The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects |journal=Gastroenterology |volume=133 |issue=1 |pages=24–33 |year=2007 |pmid=17631127 |doi=10.1053/j.gastro.2007.04.005 |url=}}</ref><ref name="pmid15667495">{{cite journal |vauthors=Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A |title=Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR |journal=Am. J. Gastroenterol. |volume=100 |issue=2 |pages=373–82 |year=2005 |pmid=15667495 |doi=10.1111/j.1572-0241.2005.40312.x |url=}}</ref><ref name="pmid21820992">{{cite journal |vauthors=Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM |title=Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome |journal=Gastroenterology |volume=141 |issue=5 |pages=1792–801 |year=2011 |pmid=21820992 |doi=10.1053/j.gastro.2011.07.043 |url=}}</ref><ref name="pmid21741921">{{cite journal |vauthors=Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J |title=Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome |journal=Gastroenterology |volume=141 |issue=5 |pages=1782–91 |year=2011 |pmid=21741921 |pmc=3417828 |doi=10.1053/j.gastro.2011.06.072 |url=}}</ref><ref name="pmid22180058">{{cite journal |vauthors=Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M |title=An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota |journal=Gut |volume=61 |issue=7 |pages=997–1006 |year=2012 |pmid=22180058 |doi=10.1136/gutjnl-2011-301501 |url=}}</ref><ref name="pmid20117111">{{cite journal |vauthors=Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK |title=Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study |journal=Gastroenterology |volume=138 |issue=5 |pages=1727–36; quiz e12 |year=2010 |pmid=20117111 |doi=10.1053/j.gastro.2010.01.043 |url=}}</ref>
** [[Gut flora|Fecal microflora]] in [[Irritable bowel syndrome|IBS]] patients differ from healthy individuals. Some IBS patients have [[Colon (anatomy)|colonic]] [[Spirochaete|spirochaetosis]], with a unique pathology of increased [[Lymphatic system|lymphoid]] follicles and [[Eosinophil granulocyte|eosinophils]] on [[histology]].<ref name="pmid20427395" /><ref name="pmid25540866">{{cite journal |vauthors=Walker MM, Talley NJ, Inganäs L, Engstrand L, Jones MP, Nyhlin H, Agréus L, Kjellstrom L, Öst Å, Andreasson A |title=Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden |journal=Hum. Pathol. |volume=46 |issue=2 |pages=277–83 |year=2015 |pmid=25540866 |doi=10.1016/j.humpath.2014.10.026 |url=}}</ref><ref name="pmid17631127">{{cite journal |vauthors=Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A |title=The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects |journal=Gastroenterology |volume=133 |issue=1 |pages=24–33 |year=2007 |pmid=17631127 |doi=10.1053/j.gastro.2007.04.005 |url=}}</ref><ref name="pmid15667495">{{cite journal |vauthors=Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A |title=Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR |journal=Am. J. Gastroenterol. |volume=100 |issue=2 |pages=373–82 |year=2005 |pmid=15667495 |doi=10.1111/j.1572-0241.2005.40312.x |url=}}</ref><ref name="pmid21820992">{{cite journal |vauthors=Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM |title=Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome |journal=Gastroenterology |volume=141 |issue=5 |pages=1792–801 |year=2011 |pmid=21820992 |doi=10.1053/j.gastro.2011.07.043 |url=}}</ref><ref name="pmid21741921">{{cite journal |vauthors=Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J |title=Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome |journal=Gastroenterology |volume=141 |issue=5 |pages=1782–91 |year=2011 |pmid=21741921 |pmc=3417828 |doi=10.1053/j.gastro.2011.06.072 |url=}}</ref><ref name="pmid22180058">{{cite journal |vauthors=Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M |title=An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota |journal=Gut |volume=61 |issue=7 |pages=997–1006 |year=2012 |pmid=22180058 |doi=10.1136/gutjnl-2011-301501 |url=}}</ref><ref name="pmid20117111">{{cite journal |vauthors=Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK |title=Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study |journal=Gastroenterology |volume=138 |issue=5 |pages=1727–36; quiz e12 |year=2010 |pmid=20117111 |doi=10.1053/j.gastro.2010.01.043 |url=}}</ref>
Line 110: Line 110:
** Increased [[serotonin]] production contributes to [[postprandial]] symptoms in [[Irritable bowel syndrome|IBS]] patients, hence providing the rationale for the therapeutic efficacy of 5-HT 3 receptor [[Receptor antagonist|antagonists]] and 5-HT 4 receptor [[Agonist|agonists]] on symptoms in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid17241888">{{cite journal |vauthors=Gershon MD, Tack J |title=The serotonin signaling system: from basic understanding to drug development for functional GI disorders |journal=Gastroenterology |volume=132 |issue=1 |pages=397–414 |year=2007 |pmid=17241888 |doi=10.1053/j.gastro.2006.11.002 |url=}}</ref><ref name="pmid22071696">{{cite journal |vauthors=Camilleri M |title=Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome |journal=Clin. Pharmacol. Ther. |volume=91 |issue=1 |pages=44–59 |year=2012 |pmid=22071696 |doi=10.1038/clpt.2011.261 |url=}}</ref>
** Increased [[serotonin]] production contributes to [[postprandial]] symptoms in [[Irritable bowel syndrome|IBS]] patients, hence providing the rationale for the therapeutic efficacy of 5-HT 3 receptor [[Receptor antagonist|antagonists]] and 5-HT 4 receptor [[Agonist|agonists]] on symptoms in [[Irritable bowel syndrome|IBS]] patients.<ref name="pmid17241888">{{cite journal |vauthors=Gershon MD, Tack J |title=The serotonin signaling system: from basic understanding to drug development for functional GI disorders |journal=Gastroenterology |volume=132 |issue=1 |pages=397–414 |year=2007 |pmid=17241888 |doi=10.1053/j.gastro.2006.11.002 |url=}}</ref><ref name="pmid22071696">{{cite journal |vauthors=Camilleri M |title=Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome |journal=Clin. Pharmacol. Ther. |volume=91 |issue=1 |pages=44–59 |year=2012 |pmid=22071696 |doi=10.1038/clpt.2011.261 |url=}}</ref>


==='''[[Psychosocial]] factors and [[CNS]] dysregulation'''===
==='''Psychosocial factors and CNS dysregulation'''===
* [[Symptom]] exacerbation occurs in [[Irritable bowel syndrome|IBS]] patients with emotional disturbances,[[Stress (medicine)|stress]], [[anxiety]] or [[depression]]. Traumatic experiences before 18 years of age directly shape adult connectivity in the executive control network consisting of structures such as the [[Insular cortex|insula]], anterior [[cingulate cortex]] and the [[thalamus]].  
* [[Symptom]] exacerbation occurs in [[Irritable bowel syndrome|IBS]] patients with emotional disturbances,[[Stress (medicine)|stress]], [[anxiety]] or [[depression]]. Traumatic experiences before 18 years of age directly shape adult connectivity in the executive control network consisting of structures such as the [[Insular cortex|insula]], anterior [[cingulate cortex]] and the [[thalamus]].  
* Semipermanent/permanent changes in complex [[Nervous system|neural]] circuits lead to central pain amplification and contribute to [[abdominal pain]] in IBS patients.<ref name="pmid27061107">{{cite journal |vauthors=Park SH, Videlock EJ, Shih W, Presson AP, Mayer EA, Chang L |title=Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity |journal=Neurogastroenterol. Motil. |volume=28 |issue=8 |pages=1252–60 |year=2016 |pmid=27061107 |pmc=4956522 |doi=10.1111/nmo.12826 |url=}}</ref><ref name="pmid25003944">{{cite journal |vauthors=Gupta A, Kilpatrick L, Labus J, Tillisch K, Braun A, Hong JY, Ashe-McNalley C, Naliboff B, Mayer EA |title=Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences |journal=Psychosom Med |volume=76 |issue=6 |pages=404–12 |year=2014 |pmid=25003944 |pmc=4113723 |doi=10.1097/PSY.0000000000000089 |url=}}</ref>
* Semipermanent/permanent changes in complex [[Nervous system|neural]] circuits lead to central pain amplification and contribute to [[abdominal pain]] in IBS patients.<ref name="pmid27061107">{{cite journal |vauthors=Park SH, Videlock EJ, Shih W, Presson AP, Mayer EA, Chang L |title=Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity |journal=Neurogastroenterol. Motil. |volume=28 |issue=8 |pages=1252–60 |year=2016 |pmid=27061107 |pmc=4956522 |doi=10.1111/nmo.12826 |url=}}</ref><ref name="pmid25003944">{{cite journal |vauthors=Gupta A, Kilpatrick L, Labus J, Tillisch K, Braun A, Hong JY, Ashe-McNalley C, Naliboff B, Mayer EA |title=Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences |journal=Psychosom Med |volume=76 |issue=6 |pages=404–12 |year=2014 |pmid=25003944 |pmc=4113723 |doi=10.1097/PSY.0000000000000089 |url=}}</ref>
Line 133: Line 133:
*'''TNF polymorphisms:'''
*'''TNF polymorphisms:'''
**[[Single nucleotide polymorphism|SNPs]] in [[Tumour necrosis factor|tumour necrosis factor alpha]] ([[Tumor necrosis factor-alpha|TNFα)]] and genes coding for superfamily member 15 (''TNFSF15'') have proven associations with [[Irritable bowel syndrome|IBS]].<ref name="pmid12477767" /><ref name="pmid22684480">{{cite journal |vauthors=Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC |title=Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα |journal=Gut |volume=62 |issue=7 |pages=985–94 |year=2013 |pmid=22684480 |doi=10.1136/gutjnl-2011-301213 |url=}}</ref><ref name="pmid21636646">{{cite journal |vauthors=Zucchelli M, Camilleri M, Andreasson AN, Bresso F, Dlugosz A, Halfvarson J, Törkvist L, Schmidt PT, Karling P, Ohlsson B, Duerr RH, Simren M, Lindberg G, Agreus L, Carlson P, Zinsmeister AR, D'Amato M |title=Association of TNFSF15 polymorphism with irritable bowel syndrome |journal=Gut |volume=60 |issue=12 |pages=1671–1677 |year=2011 |pmid=21636646 |pmc=3922294 |doi=10.1136/gut.2011.241877 |url=}}</ref>  
**[[Single nucleotide polymorphism|SNPs]] in [[Tumour necrosis factor|tumour necrosis factor alpha]] ([[Tumor necrosis factor-alpha|TNFα)]] and genes coding for superfamily member 15 (''TNFSF15'') have proven associations with [[Irritable bowel syndrome|IBS]].<ref name="pmid12477767" /><ref name="pmid22684480">{{cite journal |vauthors=Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC |title=Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα |journal=Gut |volume=62 |issue=7 |pages=985–94 |year=2013 |pmid=22684480 |doi=10.1136/gutjnl-2011-301213 |url=}}</ref><ref name="pmid21636646">{{cite journal |vauthors=Zucchelli M, Camilleri M, Andreasson AN, Bresso F, Dlugosz A, Halfvarson J, Törkvist L, Schmidt PT, Karling P, Ohlsson B, Duerr RH, Simren M, Lindberg G, Agreus L, Carlson P, Zinsmeister AR, D'Amato M |title=Association of TNFSF15 polymorphism with irritable bowel syndrome |journal=Gut |volume=60 |issue=12 |pages=1671–1677 |year=2011 |pmid=21636646 |pmc=3922294 |doi=10.1136/gut.2011.241877 |url=}}</ref>  
**[[Tumor necrosis factors|TNF]] [[polymorphisms]] are also associated with post [[Infection|infectious]] [[Irritable bowel syndrome|IBS]] such as ''rs4263839'' in ''TNFSF15'' and [[Irritable bowel syndrome|IBS]], particularly IBS associated with [[constipation]].<ref name="pmid21636646" /><ref name="pmid22684480" />
**[[Tumor necrosis factors|TNF]] [[polymorphisms]] are also associated with post [[Infection|infectious]] [[Irritable bowel syndrome|IBS]] such as ''rs4263839'' in ''TNFSF15'' and [[Irritable bowel syndrome|IBS]], particularly IBS associated with [[constipation]].<ref name="pmid22684480" /><ref name="pmid21636646" />


==Associated conditions==
==Associated conditions==
Line 143: Line 143:
===Inflammatory Bowel Disease===
===Inflammatory Bowel Disease===
* [[Irritable bowel syndrome|IBS]] and [[Inflammatory bowel disease|IBD]] are interrelated diseases, as patients with [[Inflammatory bowel disease|IBD]] experience [[Irritable bowel syndrome|IBS]]-like symptoms when their [[Inflammatory bowel disease|IBD]] is in remission.<ref name="SIMREN_2002">{{cite journal |author=Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES|title=Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors |journal=Am. J. Gastroenterol. |volume=97 |issue=2 |pages=389-96 |year=2002 |pmid=11866278 |doi=}}</ref><ref name="MINDERHOUD_2004">{{cite journal |author=Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ|title=IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior |journal=Dig. Dis. Sci. |volume=49 |issue=3 |pages=469-74 |year=2004 |pmid=15139501 |doi=}}</ref><ref name="QUIGLEY_2005">{{cite journal |author=Quigley EM |title=Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? |journal=Chinese journal of digestive diseases |volume=6 |issue=3 |pages=122-32 |year=2005 |pmid=16045602|doi=10.1111/j.1443-9573.2005.00202.x}}</ref>
* [[Irritable bowel syndrome|IBS]] and [[Inflammatory bowel disease|IBD]] are interrelated diseases, as patients with [[Inflammatory bowel disease|IBD]] experience [[Irritable bowel syndrome|IBS]]-like symptoms when their [[Inflammatory bowel disease|IBD]] is in remission.<ref name="SIMREN_2002">{{cite journal |author=Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES|title=Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors |journal=Am. J. Gastroenterol. |volume=97 |issue=2 |pages=389-96 |year=2002 |pmid=11866278 |doi=}}</ref><ref name="MINDERHOUD_2004">{{cite journal |author=Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ|title=IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior |journal=Dig. Dis. Sci. |volume=49 |issue=3 |pages=469-74 |year=2004 |pmid=15139501 |doi=}}</ref><ref name="QUIGLEY_2005">{{cite journal |author=Quigley EM |title=Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? |journal=Chinese journal of digestive diseases |volume=6 |issue=3 |pages=122-32 |year=2005 |pmid=16045602|doi=10.1111/j.1443-9573.2005.00202.x}}</ref>
* [[Irritable bowel syndrome|IBS]] is believed to be a type of low-grade [[inflammatory bowel disease]] as serum markers associated with [[inflammation]] have also been found in patients with [[Irritable bowel syndrome|IBS]] .<ref name="BERCIK_2005">{{cite journal |author=Bercik P, Verdu EF, Collins SM |title=Is irritable bowel syndrome a low-grade inflammatory bowel disease? |journal=Gastroenterol. Clin. North Am. |volume=34 |issue=2 |pages=235-45, vi-vii |year=2005|pmid=15862932 |doi=10.1016/j.gtc.2005.02.007}}</ref>  
* [[Irritable bowel syndrome|IBS]] is believed to be a type of low-grade [[inflammatory bowel disease]] as serum markers associated with [[inflammation]] have also been found in patients with [[Irritable bowel syndrome|IBS]].<ref name="BERCIK_2005">{{cite journal |author=Bercik P, Verdu EF, Collins SM |title=Is irritable bowel syndrome a low-grade inflammatory bowel disease? |journal=Gastroenterol. Clin. North Am. |volume=34 |issue=2 |pages=235-45, vi-vii |year=2005|pmid=15862932 |doi=10.1016/j.gtc.2005.02.007}}</ref>  
* [[Irritable bowel syndrome|IBS]] patients are16.3 times more likely to develop [[Inflammatory bowel disease|IBD]].<ref name="GARCIA_2000">{{cite journal |author=García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe L |title=Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome |journal=Scand. J. Gastroenterol. |volume=35 |issue=3 |pages=306-11 |year=2000 |pmid=10766326 |doi=}}</ref>   
* [[Irritable bowel syndrome|IBS]] patients are16.3 times more likely to develop [[Inflammatory bowel disease|IBD]].<ref name="GARCIA_2000">{{cite journal |author=García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe L |title=Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome |journal=Scand. J. Gastroenterol. |volume=35 |issue=3 |pages=306-11 |year=2000 |pmid=10766326 |doi=}}</ref>   


Line 157: Line 157:


===Headache, Fibromyalgia, and Depression===
===Headache, Fibromyalgia, and Depression===
[[Irritable bowel syndrome|IBS]] patients may be identified with comorbidities such as [[headache]], [[fibromyalgia]] and [[depression]].<ref>{{cite journal |author=Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA |title=Migraine,[[fibromyalgia]], and depression among people with IBS:  a prevalence study |journal=BMC gastroenterology |volume=6 |issue=|pages=26 |year=2006 |pmid=17007634 |doi=10.1186/1471-230X-6-26}}</ref><ref name="pmid16614951">{{cite journal |author=Kurland JE, Coyle WJ, Winkler A, Zable E |title=Prevalence of irritable bowel syndrome and depression in [[fibromyalgia]] |journal=Dig. Dis. Sci. |volume=51 |issue=3 |pages=454-60 |year=2006|pmid=16614951 |doi=10.1007/s10620-006-3154-7}}</ref><ref name="pmid16042909">{{cite journal |author=Frissora CL, Koch KL|title=Symptom overlap and comorbidity of irritable bowel syndrome with other conditions |journal=Current gastroenterology reports|volume=7 |issue=4 |pages=264-71 |year=2005 |pmid=16042909 |doi=}}</ref>  
[[Irritable bowel syndrome|IBS]] patients may be identified with comorbidities such as [[headache]], [[fibromyalgia]] and [[depression]].<ref name="pmid16614951">{{cite journal |author=Kurland JE, Coyle WJ, Winkler A, Zable E |title=Prevalence of irritable bowel syndrome and depression in [[fibromyalgia]] |journal=Dig. Dis. Sci. |volume=51 |issue=3 |pages=454-60 |year=2006|pmid=16614951 |doi=10.1007/s10620-006-3154-7}}</ref><ref name="pmid16042909">{{cite journal |author=Frissora CL, Koch KL|title=Symptom overlap and comorbidity of irritable bowel syndrome with other conditions |journal=Current gastroenterology reports|volume=7 |issue=4 |pages=264-71 |year=2005 |pmid=16042909 |doi=}}</ref><ref>{{cite journal |author=Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA |title=Migraine,[[fibromyalgia]], and depression among people with IBS:  a prevalence study |journal=BMC gastroenterology |volume=6 |issue=|pages=26 |year=2006 |pmid=17007634 |doi=10.1186/1471-230X-6-26}}</ref>  


===Inflammatory Bowel Disease===
===Inflammatory Bowel Disease===
Line 175: Line 175:


==Microscopic Pathology==
==Microscopic Pathology==
[[Microscopic]] changes that may be found in [[Irritable bowel syndrome|IBS]] patients are as follows:<ref name="pmid11076879">{{cite journal |vauthors=Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR |title=Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome |journal=Gut |volume=47 |issue=6 |pages=804–11 |year=2000 |pmid=11076879 |pmc=1728147 |doi= |url=}}</ref><ref name="pmid10026328">{{cite journal |vauthors=Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW |title=The role of psychological and biological factors in postinfective gut dysfunction |journal=Gut |volume=44 |issue=3 |pages=400–6 |year=1999 |pmid=10026328 |pmc=1727402 |doi= |url=}}</ref><ref name="pmid14724817">{{cite journal |vauthors=Dunlop SP, Jenkins D, Neal KR, Spiller RC |title=Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS |journal=Gastroenterology |volume=125 |issue=6 |pages=1651–9 |year=2003 |pmid=14724817 |doi= |url=}}</ref><ref name="pmid12873581">{{cite journal |vauthors=Dunlop SP, Jenkins D, Spiller RC |title=Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome |journal=Am. J. Gastroenterol. |volume=98 |issue=7 |pages=1578–83 |year=2003 |pmid=12873581 |doi=10.1111/j.1572-0241.2003.07542.x |url=}}</ref><ref name="pmid8359068">{{cite journal |vauthors=Weston AP, Biddle WL, Bhatia PS, Miner PB |title=Terminal ileal mucosal mast cells in irritable bowel syndrome |journal=Dig. Dis. Sci. |volume=38 |issue=9 |pages=1590–5 |year=1993 |pmid=8359068 |doi= |url=}}</ref><ref name="pmid11012945">{{cite journal |vauthors=O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA |title=Increased mast cells in the irritable bowel syndrome |journal=Neurogastroenterol. Motil. |volume=12 |issue=5 |pages=449–57 |year=2000 |pmid=11012945 |doi= |url=}}</ref><ref name="pmid12692417">{{cite journal |vauthors=Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC |title=Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome |journal=J. Korean Med. Sci. |volume=18 |issue=2 |pages=204–10 |year=2003 |pmid=12692417 |pmc=3055014 |doi=10.3346/jkms.2003.18.2.204 |url=}}</ref><ref name="pmid15247174">{{cite journal |vauthors=Wang LH, Fang XC, Pan GZ |title=Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis |journal=Gut |volume=53 |issue=8 |pages=1096–101 |year=2004 |pmid=15247174 |pmc=1774156 |doi=10.1136/gut.2003.021154 |url=}}</ref><ref name="pmid2733385">{{cite journal |vauthors=Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP |title=Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases |journal=Lab. Invest. |volume=60 |issue=6 |pages=847–51 |year=1989 |pmid=2733385 |doi= |url=}}</ref><ref name="pmid12454854">{{cite journal |vauthors=Törnblom H, Lindberg G, Nyberg B, Veress B |title=Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome |journal=Gastroenterology |volume=123 |issue=6 |pages=1972–9 |year=2002 |pmid=12454854 |doi=10.1053/gast.2002.37059 |url=}}</ref><ref name="pmid13907162">{{cite journal |vauthors=HIATT RB, KATZ L |title=Mast cells in inflammatory conditions of the gastrointestinal tract |journal=Am. J. Gastroenterol. |volume=37 |issue= |pages=541–5 |year=1962 |pmid=13907162 |doi= |url=}}</ref><ref name="pmid14988823">{{cite journal |vauthors=Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R |title=Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome |journal=Gastroenterology |volume=126 |issue=3 |pages=693–702 |year=2004 |pmid=14988823 |doi= |url=}}</ref>
[[Microscopic]] changes that may be found in [[Irritable bowel syndrome|IBS]] patients are as follows:<ref name="pmid12454854" /><ref name="pmid14988823" /><ref name="pmid14724817">{{cite journal |vauthors=Dunlop SP, Jenkins D, Neal KR, Spiller RC |title=Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS |journal=Gastroenterology |volume=125 |issue=6 |pages=1651–9 |year=2003 |pmid=14724817 |doi= |url=}}</ref><ref name="pmid11076879">{{cite journal |vauthors=Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR |title=Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome |journal=Gut |volume=47 |issue=6 |pages=804–11 |year=2000 |pmid=11076879 |pmc=1728147 |doi= |url=}}</ref><ref name="pmid10026328">{{cite journal |vauthors=Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW |title=The role of psychological and biological factors in postinfective gut dysfunction |journal=Gut |volume=44 |issue=3 |pages=400–6 |year=1999 |pmid=10026328 |pmc=1727402 |doi= |url=}}</ref><ref name="pmid12873581">{{cite journal |vauthors=Dunlop SP, Jenkins D, Spiller RC |title=Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome |journal=Am. J. Gastroenterol. |volume=98 |issue=7 |pages=1578–83 |year=2003 |pmid=12873581 |doi=10.1111/j.1572-0241.2003.07542.x |url=}}</ref><ref name="pmid8359068">{{cite journal |vauthors=Weston AP, Biddle WL, Bhatia PS, Miner PB |title=Terminal ileal mucosal mast cells in irritable bowel syndrome |journal=Dig. Dis. Sci. |volume=38 |issue=9 |pages=1590–5 |year=1993 |pmid=8359068 |doi= |url=}}</ref><ref name="pmid11012945">{{cite journal |vauthors=O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA |title=Increased mast cells in the irritable bowel syndrome |journal=Neurogastroenterol. Motil. |volume=12 |issue=5 |pages=449–57 |year=2000 |pmid=11012945 |doi= |url=}}</ref><ref name="pmid12692417">{{cite journal |vauthors=Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC |title=Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome |journal=J. Korean Med. Sci. |volume=18 |issue=2 |pages=204–10 |year=2003 |pmid=12692417 |pmc=3055014 |doi=10.3346/jkms.2003.18.2.204 |url=}}</ref><ref name="pmid15247174">{{cite journal |vauthors=Wang LH, Fang XC, Pan GZ |title=Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis |journal=Gut |volume=53 |issue=8 |pages=1096–101 |year=2004 |pmid=15247174 |pmc=1774156 |doi=10.1136/gut.2003.021154 |url=}}</ref><ref name="pmid2733385">{{cite journal |vauthors=Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP |title=Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases |journal=Lab. Invest. |volume=60 |issue=6 |pages=847–51 |year=1989 |pmid=2733385 |doi= |url=}}</ref><ref name="pmid13907162">{{cite journal |vauthors=HIATT RB, KATZ L |title=Mast cells in inflammatory conditions of the gastrointestinal tract |journal=Am. J. Gastroenterol. |volume=37 |issue= |pages=541–5 |year=1962 |pmid=13907162 |doi= |url=}}</ref>


{| class="wikitable"
{| class="wikitable"

Revision as of 16:14, 3 January 2018

Irritable bowel syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Irritable bowel syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Monitoring

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Case Studies

Case #1

Irritable bowel syndrome pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Irritable bowel syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Irritable bowel syndrome pathophysiology

CDC on Irritable bowel syndrome pathophysiology

Irritable bowel syndrome pathophysiology in the news

Blogs on Irritable bowel syndrome pathophysiology

Directions to Hospitals Treating Irritable bowel syndrome

Risk calculators and risk factors for Irritable bowel syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sudarshana Datta, MD [2]

Overview

Irritable Bowel Syndrome is caused by a complex interaction of various factors such as intrinsic gastrointestinal factors, CNS dysregulation and psychosocial factors, genetic, and environmental factors. Intrinsic gastrointestinal factors include motor abnormalities, visceral hypersensitivity, immune activation, mucosal inflammation, altered gut microbiota, and abnormal serotonin pathways. Visceral hypersensitivity refers to a decreased threshold for the perception of visceral stimuli that affects spinal excitability, brain stem and cortical modulation, activation of specific gastrointestinal mediators, and recruitment of peripheral silent nociceptors. Immune activation and mucosal inflammation involves an interaction of lymphocytes, mast cells, and proinflammatory cytokines. Environmental factors encompass dietary changes and infections. Psychosocial factors such as stress, anxiety, and depression directly shape adult connectivity in the executive control network consisting of structures such as the insula, anterior cingulate cortex, and the thalamus. Semipermanent or permanent changes in complex neural circuits lead to central pain amplification contributing to abdominal pain in IBS patients. The dorsolateral prefrontal cortex activity (responsible for vigilance and alertness of the human brain) and the mid-cingulate cortex (engaged in attention pathways and responses) is reduced in IBS patients. This reduction may lead to alterations in the subjective sensations of pain. Genetic factors also play a role in IBS. IBS has a high twin concordance and familial aggregation. IBS is associated with single nucleotide polymorphisms (SNPs) in genes involved in immune activation, neuropeptide hormone function, oxidative stress, nociception, permeability of the GI tract, host-microbiota interaction, inflammation, and TNF activity.

Pathophysiology

Pathogenesis

IBS occurs as a result of an interplay between four main factors:


 
 
 
 
 
CNS dysregulation and psychosocial factors
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intrinsic gastrointestinal factors:
Motor abnormalities
Visceral hypersensitivity
Immune activation and mucosal inflammation
• Altered gut microbiota
• Abnormal serotonin pathways
 
 
IRRITABLE BOWEL SYNDROME
 
 
 
Genetic factors:
• Twin concordance
• Familial aggregation
Single nucleotide polymorphisms(SNPs)
• TNF polymorphism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Environmental factors:
•Diet
•Infections
 
 
 

Environmental factors

Intrinsic gastrointestinal factors


 
 
 
 
 
 
 
 
 
 
 
 
Spinal hyperexcitability
 
Activation of
N-methyl D aspartate (NMDA) receptor
nitric oxide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Central (brainstem and cortical) modulation
 
Increased activation of:
• Anterior cingulate cortex
Thalamus
insula
 
 
 
 
 
 
 
 
 
 
 
Visceral hypersensitivity
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation of specific gastrointestinal mediators
 
Kinins and serotonin activation lead to afferent nerve fiber sensitization
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment of peripheral silent nociceptors
 
Increased end organ sensitivity due to hormonal or immune activation